Use: Labeled indications
- Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
- Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy.
- First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE Femara is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. (1.1) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy. (1.2) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer.
(1.3) 1.1 Adjuvant Treatment of Early Breast Cancer Femara (letrozole) is indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. 1.2 Extended Adjuvant Treatment of Early Breast Cancer Femara is indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of Femara in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival (DFS) in patients treated with Femara for a median of 60 months [see Clinical Studies (14.2, 14.3)]. 1.3 First and Second-Line Treatment of Advanced Breast Cancer Femara is indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer.
Femara is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see Clinical Studies (14.4, 14.5)].
Contraindications
4 CONTRAINDICATIONS Pregnancy: Letrozole can cause fetal harm [see Use in Specific Populations (8.1)]. Known hypersensitivity to the active substance, or to any of the excipients [see Adverse Reactions (6)]. Pregnancy. (4) Known hypersensitivity to the active substance, or to any of the excipients. (4)
US FDA labelDosing: Adult
- Femara tablets are taken orally without regard to meals (2): Recommended dose: 2.5 mg once daily. (2.1)
- Patients with cirrhosis or severe hepatic impairment: 2.5 mg every other day. (2.5, 5.3)
2.1 Recommended Dose
2.1 Recommended Dose The recommended dose of Femara is one 2.5 mg tablet administered once a day, without regard to meals.
2.2 Use in Adjuvant Treatment of Early Breast Cancer
2.2 Use in Adjuvant Treatment of Early Breast Cancer In the adjuvant setting, the optimal duration of treatment with letrozole is unknown. In both the adjuvant study and the post approval adjuvant study, median treatment duration was 5 years. Treatment should be discontinued at relapse [see Clinical Studies (14.1)].
2.3 Use in Extended Adjuvant Treatment of Early Breast Cancer
2.3 Use in Extended Adjuvant Treatment of Early Breast Cancer In the extended adjuvant setting, the optimal treatment duration with Femara is not known. The planned duration of treatment in the study was 5 years. In the final updated analysis, conducted at a median follow-up of 62 months, the median treatment duration for Femara was 60 months.
Seventy-one percent (71%) of patients were treated for at least 3 years and 58% of patients completed at least 4.5 years of extended adjuvant treatment. The treatment should be discontinued at tumor relapse [see Clinical Studies (14.2)].
2.4 Use in First and Second-Line Treatment of Advanced Breast Cancer
2.4 Use in First and Second-Line Treatment of Advanced Breast Cancer In patients with advanced disease, treatment with Femara should continue until tumor progression is evident [see Clinical Studies (14.4, 14.5)].
2.5 Use in Hepatic Impairment
2.5 Use in Hepatic Impairment No dosage adjustment is recommended for patients with mild to moderate hepatic impairment, although Femara blood concentrations were modestly increased in subjects with moderate hepatic impairment due to cirrhosis. The dose of Femara in patients with cirrhosis and severe hepatic dysfunction should be reduced by 50% [see Warnings and Precautions (5. 3)].
The recommended dose of Femara for such patients is 2.5 mg administered every other day. The effect of hepatic impairment on Femara exposure in noncirrhotic cancer patients with elevated bilirubin levels has not been determined.
2.6 Use in Renal Impairment
2.6 Use in Renal Impairment No dosage adjustment is required for patients with renal impairment if creatinine clearance is greater than or equal to 10 mL/min [s ee Clinical Pharmacology (12.3)].
Dosing: Altered kidney function
2.6 Use in Renal Impairment No dosage adjustment is required for patients with renal impairment if creatinine clearance is greater than or equal to 10 mL/min [s ee Clinical Pharmacology (12.3)].
Renal Impairment: In a study of volunteers with varying renal function (24-hour creatinine clearance: 9 to 116 mL/min), no effect of renal function on the pharmacokinetics of single doses of 2.5 mg of Femara was found. In addition, in a study (AR/BC2) of 347 patients with advanced breast cancer, about half of whom received 2.5 mg Femara and half 0.5 mg Femara, renal impairment (calculated creatinine clearance: 20 to 50 mL/min) did not affect steady-state plasma letrozole concentrations.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
2.5 Use in Hepatic Impairment No dosage adjustment is recommended for patients with mild to moderate hepatic impairment, although Femara blood concentrations were modestly increased in subjects with moderate hepatic impairment due to cirrhosis. The dose of Femara in patients with cirrhosis and severe hepatic dysfunction should be reduced by 50% [see Warnings and Precautions (5. 3)].
The recommended dose of Femara for such patients is 2.5 mg administered every other day. The effect of hepatic impairment on Femara exposure in noncirrhotic cancer patients with elevated bilirubin levels has not been determined.
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use The safety and effectiveness in pediatric patients have not been established. Letrozole administration to young (postnatal day 7) rats for 12 weeks duration at 0.003, 0.03, 0.3 mg/kg/day by oral gavage resulted in adverse skeletal/growth effects (bone maturation, bone mineral density) and neuroendocrine and reproductive developmental perturbations of the hypothalamic-pituitary axis.
Administration of 0.3 mg/kg/day resulted in AUC values that were similar to the AUC in adult patients receiving the recommended dose of 2.5 mg/day. Decreased fertility was accompanied by hypertrophy of the hypophysis and testicular changes that included degeneration of the seminiferous tubular epithelium and atrophy of the female reproductive tract.
Young rats in this study were allowed to recover following discontinuation of letrozole treatment for 42 days. Histopathological changes were not reversible at clinically relevant exposures.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use The median age of patients in all studies of first-line and second-line treatment of metastatic breast cancer was 64-65 years. About 1/3 of the patients were greater than or equal to 70 years old. In the first-line study, patients greater than or equal to 70 years of age experienced longer time to tumor progression and higher response rates than patients less than 70.
For the extended adjuvant setting (MA-17), more than 5,100 postmenopausal women were enrolled in the clinical study. In total, 41% of patients were aged 65 years or older at enrollment, while 12% were 75 or older. In the extended adjuvant setting, no overall differences in safety or efficacy were observed between these older patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
In the adjuvant setting (BIG 1-98), more than 8,000 postmenopausal women were enrolled in the clinical study. In total, 36% of patients were aged 65 years or older at enrollment, while 12% were 75 or older. More adverse reactions were generally reported in elderly patients irrespective of study treatment allocation. However, in comparison to tamoxifen, no overall differences with regards to the safety and efficacy profiles were observed between elderly patients and younger patients.
Dosage forms
Philippines
- Film-coated tablet: 2.5 mg
- Tablet: 2.5 mg
Registered products in the Philippines
42 products registered with the Food and Drug Administration (FDA) Philippines list Letrozole as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products42
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AlvozolLetrozole | 2.5 mg Film-Coated TabletClear PVC/PE/PVDC-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Genepharm S.A.Greece | LOTUS HEALTHCARE PHILIPPINES CORPORATIONTrader: Alvogen Emerging Markets Holdings Limited | DR-XY42905 | Nov 6, 2028 | |
BrezoleLetrozole | 2.5mg Film Coated TabletPVC/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Synthon Hispania SLSpain | Macropharma Corporation | DR-XY 47673 | Jan 25, 2027 | |
CelofemLetrozole | 2.5 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Celon Laboratories Private LimitedIndia | I.E Medica Inc. | DRP-5604 | Oct 16, 2029 | |
D-LetroxLetrozole | 2.5 mg Film-Coated TabletAlu/PVDC Blister Pack x 10 (Box of 10) | RxVAT-exempt | Renata LimitedBangladesh | Despina Pharma Inc. | DRP-17220 | Oct 21, 2030 | |
DracenaxLetrozole | 2.5 mg Film-Coated TabletPVC/PE/PVDC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Novartis Pharma Stein AGSwitzerland | Sandoz Philippines Corporation | DRP-3193 | Aug 22, 2031 | |
FEMABENELETROZOLE | 2.5 mg Film-Coated TabletAlu/PVC Blister Pack x 10's Box of 30's | RxVAT-exempt | Celon Laboratories Private LimitedIndia | Medethix, Inc.Importer: I.E Medica Inc. | DRP-5604-02 | Oct 16, 2029 | |
FemaplexLetrozole | 2.5 mg Film-Coated TabletAlu/PVC/PE/PVDC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Genepharm SaGreece | Natco Lifesciences Philippines Inc. | DRP-11519 | Dec 18, 2029 | |
FemaraLetrozole | 2.5 mg Film-Coated TabletPVC/PE/PVDC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Novartis Pharma Stein AGSwitzerland | Importer: Novartis Healthcare Philippines, Inc. | DRP-6985 | Jul 12, 2027 | |
FemzolLetrozole | 2.5mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | AMB HK Enterprises Inc. | DRP-14934 | Feb 26, 2029 | |
HENTROZOLELETROZOLE | 2.5 mg TABLETALU/PVC BLISTER PACK X 10'S (BOX OF 10'S) | RxVAT-exempt | JIANGSU-HENGRUI MEDICINE CO., LTD.China | Importer: GOODFELLOW PHARMA CORPORATION | DR-XY37413 | Jan 22, 2030 | |
HerazolLetrozole | 2.5 mg Film-Coated TabletAlu/Clear PVC blister pack x 10’s (Box of 30's) | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Kaufmann Pharma Inc.Importer: Nelpa Lifesciences, Inc. | DRP-13836-01 | Feb 8, 2028 | |
IdelaraLetrozole | 2.5 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Craveri S.A.I.C.Republica Argentina | Apolloplus Capital Inc.Trader: Bioprofarma Bago S.A. | DR-XY44453 | Apr 23, 2030 | |
KemofemLetrozole | 2.5 mg Film-Coated TabletAlu/PVC Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Globela Pharma Private LimitedIndia | Keminfinity Inc.Importer: AMB HK Enterprises Inc. | DRP-14934-01 | Feb 26, 2029 | |
LebretaLetrozole | 2.5 mg TabletAlu/PVC/PE/PVDC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Duopharma (M) Sdn. Bhd.Malaysia | Db (Philippines), Inc. | DR-XY49208 | Sep 12, 2029 | |
LeteroLetrozole | 2.5 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Hetero Labs Limited (Unit-VI)India | Camber Pharmaceuticals, Inc. | DRP-9863 | Apr 16, 2027 | |
LetoripeLetrozole | 2.5 mg TabletAlu/clear PVC Blister pack x 10's (Box of 30's) | RxVAT-exempt | Naprod Life Sciences Pvt. Ltd.India | Multicare Pharmaceuticals Phils. Inc. | DRP-2735 | Jul 9, 2031 | |
Letov 2.5Letrozole | 2.5 mg Film-Coated TabletAluminum Foil Strip x 10’s Box of 30's; Aluminum Foil Strip x 10’s Box of 100's | RxVAT-exempt | Zydus Lifesciences LimitedIndia | Zydus Healthcare Philippines Inc. | DRP-7215 | Apr 11, 2031 | |
LetrobLetrozole | 2.5mg TabletAlu/PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | AMB HK Enterprises Inc. | DRP-16733 | Jul 1, 2030 | |
Letrocord 2.5Letrozole | 2.5mg Film-Coated TabletAlu/Clear PVC/PvDC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Intas Pharmaceuticals LimitedIndia | Accord Healthcare Limited - Philippine Branch Office | DRP-8147 | Mar 27, 2029 | |
LetrodayLetrozole | 2.5 mg Film-Coated TabletAlu/clear PVC/PVDC Blister Pack (Box of 30's ) | RxVAT-exempt | Eugia Pharma Specialities LimitedIndia | MedEthix, Inc.Trader: Aurobindo Pharma Ltd. | DRP-12029 | May 31, 2027 | |
LetrogenLetrozole | 2.5 mg Film-Coated TabletAlu/PVC Blister Pack x 10’s (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | Genace Pharma DistributorImporter: AMB HK Enterprises Inc. | DRP-14934-04 | Feb 26, 2029 | |
LetroGetLetrozole | 2.5 mg Film-Coated TabletAlu/Amber PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Beta Drugs Limited.India | 2MG Incorporated | DRP-15724 | Sep 13, 2029 | |
LetroGetLetrozole | 2.5 mg Film-Coated TabletAlu-Alu Blister Pack x 10's ( Box of 30's ) | RxVAT-exempt | Hetero Labs Limited (Unit-VI)India | 2MG IncorporatedImporter: Camber Pharmaceuticals, Inc. | DRP-9863-01 | Apr 16, 2027 | |
LetroLakasLetrozole | 2.5 mg Film-Coated TabletAlu/Amber PVDC Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Beta Drugs Ltd.India | Getmeds Philippines Inc.Importer: 2MG Incorporated | DRP-15724-01 | Sep 13, 2029 | |
LetromedLetrozole | 2.5 mg TabletAlu/PVC Blister pack x 15's (Box of 30's and 90's) | RxVAT-exempt | Laboratorio Eczane Pharma S.A.Argentina | Medinova Pharmaceutical Inc. | DRP-18440 | Jul 10, 2031 | |
LetrosaphLetrozole | 2.5 mg Film-Coated TabletAlu/Clear PVC blister pack x 10's (box of 30's) | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Nelpa Lifesciences, Inc. | DRP-13836 | Feb 8, 2028 | |
LetrostadLetrozole | 2.5mg Film-coated tabletPVC/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | HAUPT PHARMA MUNSTER GMBHGermany | STADA Philippines Inc.Trader: STADA Arzneimittel AG | DRP-4394 | Feb 13, 2028 | |
LetrozLetrozole | 2.5 mg Film-Coated TabletAlu/PVC Blister Pack x 10’s Box of 30’s | RxVAT-exempt | Sun Pharmaceutical Industries Ltd.India | Sun Pharma Philippines, Inc. | DRP-8741 | Dec 6, 2028 | |
LetvexLetrozole | 2.5 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | ADMAC LifesciencesIndia | VE Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd. | DR-XY44958 | Dec 21, 2030 | |
LezolLetrozole | 2.5 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Intas Pharmaceuticals LimitedIndia | Oncolife Corporation | DRP-7192 | Oct 11, 2030 | |
MamazolLetrozole | 2.5 mg Film-Coated TabletAluminum Foil Strip x 10's (Box of 30's) | RxVAT-exempt | Khandelwal Laboratories Pvt. Ltd.India | Medethix, Inc. | DRP-6572 | Mar 16, 2031 | |
MedrozoleLetrozole | 2.5 mg Film-Coated TabletAluminum Foil Strip x 10's (Box of 30's) | RxVAT-exempt | Khandelwal Laboratories Pvt. Ltd.India | I.E. Medica, Inc.Importer: Medethix, Inc. | DRP-6572-02 | Mar 16, 2031 | |
NeulyLetrozole | 2.5 mg Film-Coated TabletAlu/Alu Blister Pack x 10 (Box of 10) | RxVAT-exempt | Pharmix Laboratories (Pvt.) Ltd.Pakistan | Sahar International Trading Inc. | DR-XY49562 | Oct 21, 2030 | |
NeulyLetrozole | 2.5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's and 30's) | RxVAT-exempt | Pharmix Laboratories (Pvt) LtdPakistan | Sahar International Trading, Inc. | DRP-17884 | Oct 21, 2030 | |
NoneLetrozole | 2.5 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Celon Laboratories Private LimitedIndia | Medethix, Inc.Importer: I.E. Medica, Inc. | DRP-5604-01 | Oct 16, 2029 | |
OvaliaLetrozole | 2.5 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | Corbridge Group Phils., Inc.Importer: AMB HK Enterprises Inc. | DRP-14934-02 | Feb 26, 2029 | |
OvupicLetrozole | 2.5 mg Film-Coated TabletAlu/Clear PVC blister pack x 10’s (Box of 30’s) | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc. | DRP-13836-02 | Feb 8, 2028 | |
RapizoleLetrozole | 2.5 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Pacific Pharmaceuticals Limited.Pakistan | Raquel Abbas Pharma Inc. | DRP-16433 | Mar 11, 2030 | |
UnbrandedLetrozole | 2.5 mg Film- Coated tabletAluminum Foil Strip x 10's (Box of 30's) | RxVAT-exempt | Khandelwal Laboratories Pvt. Ltd.India | I.E. Medica, Inc.Importer: Medethix, Inc. | DRP-6572-01 | Mar 16, 2031 | |
WandaLetrozole | 2.5 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | Kaufmann Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-14934-03 | Feb 26, 2029 | |
XenazoleLetrozole | 2.5 mg Film-Coated TabletPVC/PE/PVDC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Novartis Pharma Stein AGSwitzerland | UNILAB, Inc.Importer: Sandoz Philippines Corporation | DRP-3193-01 | Aug 22, 2031 | |
(no brand name)Letrozole | 2.5 mg Film-Coated TabletAlu/clear PVC/PVDC Blister Pack (Box of 30's) | RxVAT-exempt | Eugia Pharma Specialities LimitedIndia | MedEthix, Inc.Trader: Aurobindo Pharma Ltd. | DRP-12030 | May 31, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS 2.5 mg tablets: dark yellow, film-coated, round, slightly biconvex, with beveled edges (imprinted with the letters ‘FV’ on one side and ‘CG’ on the other side). 2.5 mg tablets. (3)
Warnings/Precautions
- Decreases in bone mineral density may occur. Consider bone mineral density monitoring. (5.1)
- Increases in total cholesterol may occur. Consider cholesterol monitoring. (5.2)
- Fatigue, dizziness, and somnolence may occur. Exercise caution when operating machinery. (5.4)
- Embryo-Fetal Toxicity: Can cause fetal harm when administered to pregnant women. Obtain a pregnancy test in females of reproductive potential. Advise females of reproductive potential to use effective contraception. (5.6, 8.1, 8.3)
5.1 Bone Effects Use
5.1 Bone Effects Use of Femara may cause decreases in bone mineral density (BMD). Consideration should be given to monitoring BMD. Results of a safety study to evaluate safety in the adjuvant setting comparing the effect on lumbar spine (L2-L4) BMD of adjuvant treatment with letrozole to that with tamoxifen showed at 24 months a median decrease in lumbar spine BMD of 4.1% in the letrozole arm compared to a median increase of 0.3% in the tamoxifen arm (difference = 4.4%) (P < 0.0001) [s ee Adverse Reactions (6)].
Updated results from the BMD substudy (MA-17B) in the extended adjuvant setting demonstrated that at 2 years patients receiving letrozole had a median decrease from baseline of 3.8% in hip BMD compared to a median decrease of 2.0% in the placebo group. The changes from baseline in lumbar spine BMD in letrozole and placebo treated groups were not significantly different [see Adverse Reactions (6)].
In the adjuvant trial (BIG 1-98) the incidence of bone fractures at any time after randomization was 14.7% for letrozole and 11.4% for tamoxifen at a median follow-up of 96 months. The incidence of osteoporosis was 5.1% for letrozole and 2.7% for tamoxifen [s ee Adver se R eactions (6)]. In the extended adjuvant trial (MA-17), the incidence of bone fractures at any time after randomization was 13.3% for letrozole and 7.8% for placebo at a median follow-up of 62 months.
The incidence of new osteoporosis was 14.5% for letrozole and 7.8% for placebo [s ee Adverse Reactions (6)].
5.2 Cholesterol
5.2 Cholesterol Consideration should be given to monitoring serum cholesterol. In the adjuvant trial (BIG 1-98), hypercholesterolemia was reported in 52.3% of letrozole patients and 28.6% of tamoxifen patients. Grade 3-4 hypercholesterolemia was reported in 0.4% of letrozole patients and 0.1% of tamoxifen patients. Also in the adjuvant setting, an increase of greater than or equal to 1.5 x upper limit of normal (ULN) in total cholesterol (generally nonfasting) was observed in patients on monotherapy who had baseline total serum cholesterol within the normal range (i.e., less than = 1.5 x ULN) in 155/1843 (8.4%) patients on letrozole vs 71/1840 (3.9%) patients on tamoxifen Lipid lowering medications were required for 29% of patients on letrozole and 20% on tamoxifen [s ee Adverse R eactions (6)].
5.3 Hepatic Impairment
5.3 Hepatic Impairment Subjects with cirrhosis and severe hepatic impairment who were dosed with 2.5 mg of Femara experienced approximately twice the exposure to Femara as healthy volunteers with normal liver function [see Clinical Pharmacology (12.3)]. Therefore, a dose reduction is recommended for this patient population.
The effect of hepatic impairment on Femara exposure in cancer patients with elevated bilirubin levels has not been determined [see Dosage and Administration (2. 5)].
5.4 Fatigue and Dizziness
5.4 Fatigue and Dizziness Because fatigue, dizziness, and somnolence have been reported with the use of Femara, caution is advised when driving or using machinery until it is known how the patient reacts to Femara use.
5.5 Laboratory Test Abnormalities
5.5 Laboratory Test Abnormalities No dose-related effect of Femara on any hematologic or clinical chemistry parameter was evident. Moderate decreases in lymphocyte counts, of uncertain clinical significance, were observed in some patients receiving Femara 2.5 mg. This depression was transient in about half of those affected.
Two patients on Femara developed thrombocytopenia; relationship to the study drug was unclear. Patient withdrawal due to laboratory abnormalities, whether related to study treatment or not was infrequent.
5.6 Embryo-Fetal Toxicity
5.6 Embryo-Fetal Toxicity Based on post-marketing reports, findings from animal studies and the mechanism of action, Femara can cause fetal harm and is contraindicated for use in pregnant women. In post-marketing reports, use of letrozole during pregnancy resulted in cases of spontaneous abortions and congenital birth defects.
Letrozole caused embryo-fetal toxicities in rats and rabbits at maternal exposures that were below the maximum recommended human dose (MHRD) on a mg/m 2 basis. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during therapy with Femara and for at least 3 weeks after the last dose [see Adverse Reactions (6.2), Use in Specific Populations (8.1, 8.3), and Clinical Pharmacology (12.1)].
Drug interactions
Drug interactions (US label) US FDA label
7 DRUG INTERACTIONS Tamoxifen Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels of 38% on average (Study P015). Clinical experience in the second-line breast cancer trials (AR/BC2 and AR/BC3) indicates that the therapeutic effect of Femara therapy is not impaired if Femara is administered immediately after tamoxifen.
Cimetidine A pharmacokinetic interaction study with cimetidine (Study P004) showed no clinically significant effect on letrozole pharmacokinetics. Warfarin An interaction study (P017) with warfarin showed no clinically significant effect of letrozole on warfarin pharmacokinetics. Other Anticancer Agents There is no clinical experience to date on the use of Femara in combination with other anticancer agents.
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
In human microsomes with specific CYP isozyme activity, CYP3A4 metabolized letrozole to the carbinol metabolite while CYP2A6 formed both this metabolite and its ketone analog.
In human liver microsomes, letrozole inhibited CYP2A6 and CYP2C19, however, the clinical significance of these findings is unknown.
Adverse reactions
The following adverse reactions are discussed in greater detail in other sections of the labeling. Bone effects [see Warnings and Precautions (5.1)] Increases in cholesterol [see Warnings and Precautions (5.2)] Fatigue and Dizziness [see Warnings and Precautions (5.4)] The most common adverse reactions (greater than 20%) were hot flashes, arthralgia; flushing, asthenia, edema, arthralgia, headache, dizziness, hypercholesterolemia, sweating increased, bone pain; and musculoskeletal.
(6) To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adjuvant Treatment of Early Breast Cancer In study, BIG 1-98, the median treatment duration of adjuvant treatment was 60 months and the median duration of follow-up for safety was 96 months for patients receiving Femara and tamoxifen.
Certain adverse reactions were prospectively specified for analysis (see Table 1), based on the known pharmacologic properties and side effect profiles of the two drugs. Adverse reactions were analyzed irrespective of whether a symptom was present or absent at baseline. Most adverse reactions reported (approximately 75% of patients who reported AEs) were Grade 1 or Grade 2 applying the Common Toxicity Criteria (CTC) Version 2.0/Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0.
Table 1 describes adverse reactions (Grades 1-4 and Grades 3-4) irrespective of relationship to study treatment in the adjuvant trial for the monotherapy arms analysis (safety population). Table 1: Patients With Adverse Reactions (CTC Grades 1-4) in the Adjuvant Study – Monotherapy Arms Analysis (Median Follow-up 96 Months; Median Treatment 60 Months) Grades 1-4 Grades 3-4 Femara Tamoxifen Femara Tamoxifen Adverse R eaction s N = 2448 N = 2447 N = 2448 N = 2447 n (%) n (%) n (%) n (%) Patients with any adverse reaction 2309 (94.3) 2212 (90.4) 636 (26.0) 606 (24.8) Hypercholesterolemia* 1280 (52.3) 700 (28.6) 11 (0.4) 6 (0.2) Hot flashes* 819 (33.5) 929 (38.0) - - - - Arthralgia/arthritis* 621 (25.4) 504 (20.6) 84 (3.4) 50 (2.0) Bone fractures 1 361 (14.7) 280 (11.4) - - - - Night sweats* 356 (14.5) 426 (17.4) - - - - Weight increase* 317 (12.9) 378 (15.4) 27 (1.1) 39 (1.6) Nausea* 284 (11.6) 277 (11.3) 6 (0.2) 9 (0.4) Bone fractures** 2 249 (10.2) 175 (7.2) - - - - Fatigue (lethargy, malaise, asthenia)* 235 (9.6) 250 (10.2) 6 (0.2) 7 (0.3) Myalgia* 221 (9.0) 212 (8.7) 18 (0.7) 14 (0.6) Vaginal bleeding* 129 (5.3) 320 (13.1) 1 (< 0.1) 8 (0.3) Edema* 164 (6.7) 160 (6.5) 3 (0.1) 1 (< 0.1) Weight decrease 140 (5.7) 129 (5.3) 8 (0.3) 5 (0.2) Osteoporosis** 126 (5.1) 67 (2.7) 10 (0.4) 5 (0.2) Back pain 125 (5.1) 136 (5.6) 7 (0.3) 11 (0.4) Bone pain 123 (5.0) 109 (4.5) 6 (0.2) 4 (0.2) Depression 119 (4.9) 114 (4.7) 16 (0.7) 14 (0.6) Vaginal irritation* 112 (4.6) 77 (3.1) 2 (< 0.1) 2 (< 0.1) Headache* 105 (4.3) 94 (3.8) 8 (0.3) 4 (0.2) Pain in extremity 103 (4.2) 79 (3.2) 6 (0.2) 4 (0.2) Osteopenia* 87 (3.6) 76 (3.1) 0 - 3 (0.1) Dizziness/light-headedness* 84 (3.4) 80 (3.3) 1 (< 0.1) 6 (0.2) Alopecia 83 (3.4) 84 (3.4) - - - - Vomiting* 80 (3.3) 80 (3.3) 3 (0.1) 5 (0.2) Cataract* 49 (2.0) 54 (2.2) 16 (0.7) 17 (0.7) Constipation* 49 (2.0) 71 (2.9) 3 (0.1) 1 (< 0.1) Myocardial infarction 1 42 (1.7) 28 (1.1) - - - - Breast pain* 37 (1.5) 43 (1.8) 1 (< 0.1) - - Anorexia* 20 (0.8) 20 (0.8) 1 (< 0.1) 1 (< 0.1) Endometrial proliferation disorders* 14 (0.6) 86 (3.5) 0 - 14 (0.6) Ovarian cyst* 11 (0.4) 18 (0.7) 4 (0.2) 4 (0.2) Endometrial hyperplasia/cancer** 1 11 (0.4) 72 (2.9) - - - - Endometrial hyperplasia/cancer**, 3 6/1909 (0.3) 57/1943 (2.9) - - - - Other endometrial disorders* 2 (< 0.1) 3 (0.1) 0 - 0 - Myocardial infarction** 2 24 (1.0) 12 (0.5) - - - - Myocardial ischemia 6 (0.2) 9 (0.4) - - - - Cerebrovascular accident/TIA** 1 74 (3.0) 68 (2.8) - - - - Cerebrovascular accident/TIA** 2 51 (2.1) 47 (1.9) - - - - Angina requiring surgery** 1 35 (1.4) 33 (1.3) - - - - Angina requiring surgery** 2 25 (1.0) 25 (1.0) - - - - Thromboembolic event** 1 79 (3.2) 113 (4.6) - - - - Thromboembolic event** 2 51 (2.1) 89 (3.6) - - - - Cardiac failure 1 39 (1.6) 34 (1.4) - - - - Cardiac failure 2 27 (1.1) 15 (0.6) - - - - Hypertension 1 160 (6.5) 175 (7.2) - - - - Hypertension 2 138 (5.6) 139 (5.7) - - - - Other cardiovascular** 1 172 (7.0) 174 (7.1) - - - - Other cardiovascular** 2 120 (4.9) 119 (4.9) - - - - Second primary malignancy 1 129 (5.3) 150 (6.1) - - - - Second primary malignancy 2 54 (2.2) 79 (3.2) - - - - *Target events pre-specified for analysis **Events pre-printed on CRF 1 At median follow-up of 96 months (i.e., any time after randomization) for Femara (range up to 144 months) and 95 months for tamoxifen (range up to 143 months). 2 At median treatment duration of 60 months (i.e. during treatment + 30 days after discontinuation of treatment) for Femara and tamoxifen (range up to 68 months). 3 Excluding women who had undergone hysterectomy before study entry.
TIA = Transient ischemic attack. Note: Cardiovascular events (including cerebrovascular and thromboembolic events), skeletal and urogenital/endometrial events and second primary malignancies were collected life -long. All of these events were assumed to be of CTC Grade 3 to 5 and were not individually graded. When considering all grades during study treatment, a higher incidence of events was seen for Femara regarding fractures (10.1% vs 7.1%), myocardial infarctions (1.0% vs 0.5%), and arthralgia (25.2% vs 20.4%) (Femara vs tamoxifen respectively).
A higher incidence was seen for tamoxifen regarding thromboembolic events (2.1% vs 3.6%), endometrial hyperplasia/cancer (0.3% vs 2.9%), and endometrial proliferation disorders (0.3% vs 1.8%) (Femara vs tamoxifen respectively). At a median follow-up of 96 months, a higher incidence of events was seen for Femara (14.7%) than for tamoxifen (11.4%) regarding fractures.
A higher incidence was seen for tamoxifen compared to Femara regarding thromboembolic events (4.6% vs 3.2%), and endometrial hyperplasia or cancer (2.9% vs 0.4%) (tamoxifen vs Femara, respectively). Bone Study: Results of a safety trial in 263 postmenopausal women with resected receptor positive early breast cancer in the adjuvant setting comparing the effect on lumbar spine (L2-L4) BMD of adjuvant treatment with letrozole to that with tamoxifen showed at 24 months a median decrease in lumbar spine BMD of 4.1% in the letrozole arm compared to a median increase of 0.3% in the tamoxifen arm (difference = 4.4%) (P < 0.0001).
No patients with a normal BMD at baseline became osteoporotic over the 2 years and only 1 patient with osteopenia at baseline (T score of -1.9) developed osteoporosis during the treatment period (assessment by central review). The results for total hip BMD were similar, although the differences between the two treatments were less pronounced.
During the 2 year period, fractures were reported by 4 of 103 patients (4%) in the letrozole arm, and 6 of 97 patients (6%) in the tamoxifen arm. Lipid Study: In a safety trial in 263 postmenopausal women with resected receptor positive early breast cancer at 24 months comparing the effects on lipid profiles of adjuvant letrozole to tamoxifen, 12% of patients on letrozole had at least one total cholesterol value of a higher CTCAE grade than at baseline compared with 4% of patients on tamoxifen.
In another postapproval randomized, multicenter, open label, study of letrozole vs anastrozole in the adjuvant treatment of postmenopausal women with hormone receptor and node positive breast cancer (FACE, NCT00248170), the median duration of treatment was 60 months for both treatment arms. Table 2 describes adverse reactions (Grades 1-4 and Grades 3-4) irrespective of relationship to study treatment in the adjuvant study (safety population).
Table 2: Adverse Reactions (CTC Grades 1-4), Occurring in at Least 5% of Patients in Either Treatment Arm, by Preferred Term (Safety set) Adverse Reactions Letrozole N = 2049 n (%) Anastrozole N = 2062 n (%) Grade 3/4 n (%) All Grades n (%) Grade 3/4 n (%) All Grades n (%) Patients with at least one AR 628 (30.6) 2049 (100.0) 591 (28.7) 2062 (100.0) Arthralgia 80 (3.9) 987 (48.2) 69 (3.3) 987 (47.9) Hot flush 17 (0.8) 666 (32.5) 9 (0.4) 666 (32.3) Fatigue 8 (0.4) 345 (16.8) 10 (0.5) 343 (16.6) Osteoporosis 5 (0.2) 223 (10.9) 11 (0.5) 225 (10.9) Myalgia 16 (0.8) 233 (11.4) 15 (0.7) 212 (10.3) Back pain 11 (0.5) 212 (10.3) 17 (0.8) 193 (9.4) Osteopenia 4 (0.2) 203 (9.9) 1 (0.0) 173 (8.4) Pain in extremity 9 (0.4) 168 (8.2) 3 (0.1) 174 (8.4) Lymphoedema 5 (0.2) 159 (7.8) 2 (0.1) 179 (8.7) Insomnia 7 (0.3) 160 (7.8) 3 (0.1) 149 (7.2) Hypercholesterolaemia 2 (0.1) 155 (7.6) 1 (0.0) 151 (7.3) Hypertension 25 (1.2) 156 (7.6) 20 (1.0) 149 (7.2) Depression 16 (0.8) 147 (7.2) 13 (0.6) 137 (6.6) Bone pain 10 (0.5) 138 (6.7) 9 (0.4) 122 (5.9) Nausea 6 (0.3) 137 (6.7) 5 (0.2) 152 (7.4) Headache 3 (0.1) 130 (6.3) 5 (0.2) 168 (8.1) Alopecia 2 (0.1) 127 (6.2) 0 (0.0) 134 (6.5) Musculoskeletal pain 6 (0.3) 123 (6.0) 9 (0.4) 147 (7.1) Radiation skin injury 11 (0.5) 120 (5.9) 6 (0.3) 88 (4.3) Dyspnea 16 (0.8) 118 (5.8) 10 (0.5) 96 (4.7) Cough 1 (0.0) 106 (5.2) 1 (0.0) 120 (5.8) Musculoskeletal stiffness 2 (0.1) 102 (5.0) 2 (0.1) 84 (4.1) Dizziness 2 (0.2) 94 (4.6) 7 (0.3) 109 (5.3) The following adverse reactions were also identified in less than 5% of the 2049 patients treated with letrozole and not included in the table: fall, vertigo, hyperbilirubinemia, jaundice, and chest pain. Extended Adjuvant Treatment of Early Breast Cancer, Median Treatment Duration of 24 M onths In study MA-17, the median duration of extended adjuvant treatment was 24 months and the median duration of follow-up for safety was 28 months for patients receiving Femara and placebo.
Table 3 describes the adverse reactions occurring at a frequency of at least 5% in any treatment group during treatment. Most adverse reactions reported were Grade 1 and Grade 2 based on the CTC Version 2.0. In the extended adjuvant setting, the reported drug-related adverse reactions that were significantly different from placebo were hot flashes, arthralgia/arthritis, and myalgia.
Table 3: Adverse Reactions Occurring in at Least 5% of Patients in Either Treatment Arm Number (%) of Patients with Grade 1-4 Adverse Reaction s Number (%) of Patients with Grade 3-4 Adverse Reaction s Femara Placebo Femara Placebo N = 2563 N = 2573 N = 2563 N = 2573 Any Adverse Reaction s 2232 (87.1) 2174 (84.5) 419 (16.3) 389 (15.1) Vascular Disorders 1375 (53.6) 1230 (47.8) 59 (2.3) 74 (2.9) Flushing 1273 (49.7) 1114 (43.3) 3 (0.1) 0 General Disorders 1154 (45) 1090 (42.4) 30 (1.2) 28 (1.1) Asthenia 862 (33.6) 826 (32.1) 16 (0.6) 7 (0.3) Edema NOS 471 (18.4) 416 (16.2) 4 (0.2) 3 (0.1) Musculoskeletal Disorders 978 (38.2) 836 (32.5) 71 (2.8) 50 (1.9) Arthralgia 565 (22) 465 (18.1) 25 (1) 20 (0.8) Arthritis NOS 173 (6.7) 124 (4.8) 10 (0.4) 5 (0.2) Myalgia 171 (6.7) 122 (4.7) 8 (0.3) 6 (0.2) Back Pain 129 (5) 112 (4.4) 8 (0.3) 7 (0.3) Nervous System Disorders 863 (33.7) 819 (31.8) 65 (2.5) 58 (2.3) Headache 516 (20.1) 508 (19.7) 18 (0.7) 17 (0.7) Dizziness 363 (14.2) 342 (13.3) 9 (0.4) 6 (0.2) Skin Disorders 830 (32.4) 787 (30.6) 17 (0.7) 16 (0.6) Sweating Increased 619 (24.2) 577 (22.4) 1 (< 0.1) 0 Gastrointestinal Disorders 725 (28.3) 731 (28.4) 43 (1.7) 42 (1.6) Constipation 290 (11.3) 304 (11.8) 6 (0.2) 2 (< 0.1) Nausea 221 (8.6) 212 (8.2) 3 (0.1) 10 (0.4) Diarrhea NOS 128 (5) 143 (5.6) 12 (0.5) 8 (0.3) Metabolic Disorders 551 (21.5) 537 (20.9) 24 (0.9) 32 (1.2) Hypercholesterolemia 401 (15.6) 398 (15.5) 2 (< 0.1) 5 (0.2) Reproductive Disorders 303 (11.8) 357 (13.9) 9 (0.4) 8 (0.3) Vaginal Hemorrhage 123 (4.8) 171 (6.6) 2 (< 0.1) 5 (0.2) Vulvovaginal Dryness 137 (5.3) 127 (4.9) 0 0 Psychiatric Disorders 320 (12.5) 276 (10.7) 21 (0.8) 16 (0.6) Insomnia 149 (5.8) 120 (4.7) 2 (< 0.1) 2 (< 0.1) Respiratory Disorders 279 (10.9) 260 (10.1) 30 (1.2) 28 (1.1) Dyspnea 140 (5.5) 137 (5.3) 21 (0.8) 18 (0.7) Investigations 184 (7.2) 147 (5.7) 13 (0.5) 13 (0.5) Infections and Infestations 166 (6.5) 163 (6.3) 40 (1.6) 33 (1.3) Renal Disorders 130 (5.1) 100 (3.9) 12 (0.5) 6 (0.2) Based on a median follow-up of patients for 28 months, the incidence of clinical fractures from the core randomized study in patients who received Femara was 5.9% (152) and placebo was 5.5% (142). The incidence of self-reported osteoporosis was higher in patients who received Femara 6.9% (176) than in patients who received placebo 5.5% (141).
Bisphosphonates were administered to 21.1% of the patients who received Femara and 18.7% of the patients who received placebo. The incidence of cardiovascular ischemic events from the core randomized study was comparable between patients who received Femara 6.8% (175) and placebo 6.5% (167). A patient-reported measure that captures treatment impact on important symptoms associated with estrogen deficiency demonstrated a difference in favor of placebo for vasomotor and sexual symptom domains.
Bone Substudy: [s ee Warnings and Preca u tions (5. 1)] Lipid Substudy: In the extended adjuvant setting, based on a median duration of follow-up of 62 months, there was no significant difference between Femara and placebo in total cholesterol or in any lipid fraction at any time over 5 years. Use of lipid lowering drugs or dietary management of elevated lipids was allowed [see Warnings and Precautions (5.2)].
Updated Analy s is, Extended Adjuvant Treatment of Early Breast Cancer, Median Treatment Duration of 60 Months The extended adjuvant treatment trial (MA-17) was unblinded early [see Adverse Reactions (6)]. At the updated (final analysis), overall the side effects seen were consistent to those seen at a median treatment duration of 24 months.
During treatment or within 30 days of stopping treatment (median duration of treatment 60 months) a higher rate of fractures was observed for Femara (10.4%) compared to placebo (5.8%), as also a higher rate of osteoporosis (Femara 12.2% vs placebo 6.4%). Based on 62 months median duration of follow-up in the randomized letrozole arm in the safety population the incidence of new fractures at any time after randomization was 13.3% for letrozole and 7.8% for placebo.
The incidence of new osteoporosis was 14.5% for letrozole and 7.8% for placebo. During treatment or within 30 days of stopping treatment (median duration of treatment 60 months), the incidence of cardiovascular events was 9.8% for Femara and 7.0% for placebo. Based on 62 months median duration of follow-up in the randomized letrozole arm in the safety population the incidence of cardiovascular disease at any time after randomization was 14.4% for letrozole and 9.8% for placebo.
Lipid Substudy: In the extended adjuvant setting (MA-17), based on a median duration of follow-up of 62 months, there was no significant difference between Femara and placebo in total cholesterol or in any lipid fraction over 5 years. Use of lipid lowering drugs or dietary management of elevated lipids was allowed [see Warnings and Precautions (5.2)].
First-Line Treatment of Advanced Breast Cancer In study P025 a total of 455 patients were treated for a median time of exposure of 11 months in the Femara arm (median 6 months in the tamoxifen arm). The incidence of adverse reactions was similar for Femara and tamoxifen. The most frequently reported adverse reactions were bone pain, hot flushes, back pain, nausea, arthralgia, and dyspnea.
Discontinuations for adverse reactions other than progression of tumor occurred in 10/455 (2%) of patients on Femara and in 15/455 (3%) of patients on tamoxifen. Adverse reactions that were reported in at least 5% of the patients treated with Femara 2.5 mg or tamoxifen 20 mg in the first-line treatment study are shown in Table 4.
Table 4: Adverse Reactions Occurring in at Least 5% of Patients in Either Treatment Arm Adverse Reactions Femara Tamoxifen 2.5 mg 20 mg (N = 455) (N = 455) % % General Disorders Fatigue 13 13 Chest Pain 8 9 Edema Peripheral 5 6 Pain NOS 5 7 Weakness 6 4 Investigations Weight Decreased 7 5 Vascular Disorders Hot Flushes 19 16 Hypertension 8 4 Gastrointestinal Disorders Nausea 17 17 Constipation 10 11 Diarrhea 8 4 Vomiting 7 8 Infections/Infestations Influenza 6 4 Urinary Tract Infection NOS 6 3 Injury, Poisoning and Procedural Complications Post-Mastectomy Lymphedema 7 7 Metabolism and Nutrition Disorders Anorexia 4 6 Musculoskeletal and Connective Tissue Disorders Bone Pain 22 21 Back Pain 18 19 Arthralgia 16 15 Pain in Limb 10 8 Nervous System Disorders Headache NOS 8 7 Psychiatric Disorders Insomnia 7 4 Reproductive System and Breast Disorders Breast Pain 7 7 Respiratory, Thoracic and Mediastinal Disorders Dyspnea 18 17 Cough 13 13 Chest Wall Pain 6 6 Other less frequent (less than or equal to 2%) adverse reactions considered consequential for both treatment groups, included peripheral thromboembolic events, cardiovascular events, and cerebrovascular events. Peripheral thromboembolic events included venous thrombosis, thrombophlebitis, portal vein thrombosis, and pulmonary embolism.
Cardiovascular events included angina, myocardial infarction, myocardial ischemia, and coronary heart disease. Cerebrovascular events included transient ischemic attacks, thrombotic or hemorrhagic strokes, and development of hemiparesis. Second-Line Treatment of Advanced Breast Cancer Study discontinuations in the megestrol acetate comparison study (AR/BC2) for adverse reactions other than progression of tumor were 5/188 (2.7%) on Femara 0.5 mg, in 4/174 (2.3%) on Femara 2.5 mg, and in 15/190 (7.9%) on megestrol acetate.
There were fewer thromboembolic events at both Femara doses than on the megestrol acetate arm (0.6% vs 4.7%). There was also less vaginal bleeding (0.3% vs 3.2%) on Femara than on megestrol acetate. In the aminoglutethimide comparison study (AR/BC3), discontinuations for reasons other than progression occurred in 6/193 (3.1%) on 0.5 mg Femara, 7/185 (3.8%) on 2.5 mg Femara, and 7/178 (3.9%) of patients on aminoglutethimide.
Comparisons of the incidence of adverse reactions revealed no significant differences between the high and low dose Femara groups in either study. Most of the adverse reactions observed in all treatment groups were mild to moderate in severity and it was generally not possible to distinguish adverse reactions due to treatment from the consequences of the patient’s metastatic breast cancer, the effects of estrogen deprivation, or intercurrent illness.
Adverse reactions that were reported in at least 5% of the patients treated with Femara 0.5 mg, Femara 2.5 mg, megestrol acetate, or aminoglutethimide in the two controlled trials AR/BC2 and AR/BC3 are shown in Table 5. Table 5: Adverse Reactions Occurring at a Frequency of at Least 5% of Patients in Either Treatment Arm 1 Includes peripheral edema, leg edema, dependent edema, edema. 2 Includes musculoskeletal pain, skeletal pain, back pain, arm pain, leg pain. 3 Includes rash, erythematous rash, maculopapular rash, psoriasiform rash, vesicular rash.
Adverse Reactions Pooled Pooled Megestrol Femara Femara Acetate Aminoglutethimide 2.5 mg 0.5 mg 160 mg 500 mg (N = 359) (N = 380) (N = 189) (N = 178) % % % % Body as a Whole Chest Pain 6 3 7 3 Peripheral Edema 1 5 5 8 3 Asthenia 4 5 4 5 Weight Increase 2 2 9 3 Cardiovascular Hypertension 5 7 5 6 Digestive System Nausea 13 15 9 14 Vomiting 7 7 5 9 Constipation 6 7 9 7 Diarrhea 6 5 3 4 Pain-Abdominal 6 5 9 8 Anorexia 5 3 5 5 Dyspepsia 3 4 6 5 Infections/Infestations Viral Infection 6 5 6 3 Lab Abnormality Hypercholesterolemia 3 3 0 6 Musculoskeletal System Musculoskeletal 2 21 22 30 14 Arthralgia 8 8 8 3 Nervous System Headache 9 12 9 7 Somnolence 3 2 2 9 Dizziness 3 5 7 3 Respiratory System Dyspnea 7 9 16 5 Coughing 6 5 7 5 Skin and Appendages Hot Flushes 6 5 4 3 Rash 3 5 4 3 12 Pruritus 1 2 5 3 Other less frequent (less than 5%) adverse reactions considered consequential and reported in at least 3 patients treated with Femara, included hypercalcemia, fracture, depression, anxiety, pleural effusion, alopecia, increased sweating, and vertigo. First and Second-Line Treatment of Advanced Breast Cancer In the combined analysis of the first- and second-line metastatic trials and postmarketing experiences other adverse reactions that were reported were cataract, eye irritation, palpitations, cardiac failure, tachycardia, dysesthesia (including hypesthesia/paresthesia), arterial thrombosis, memory impairment, irritability, nervousness, urticaria, increased urinary frequency, leukopenia, stomatitis cancer pain, pyrexia, vaginal discharge, appetite increase, dryness of skin and mucosa (including dry mouth), and disturbances of taste and thirst.
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of Femara. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Eye Disorders: blurred vision Hepatobiliary Disorders: increased hepatic enzymes, hepatitis Immune System Disorders: anaphylactic reactions, hypersensitivity reactions Nervous System Disorders: carpal tunnel syndrome Pregnancy: spontaneous abortions, congenital birth defects Skin and subcutaneous disorders: angioedema, toxic epidermal necrolysis, erythema multiforme Musculoskeletal and connective tissue disorders: tendon disorders including tendon rupture, tendonitis, tenosynovitis, and tenosynovitis stenosans (trigger finger)
Adverse reaction frequency tables (US label) US FDA label
| Grades 1-4 | Grades 3-4 | |||||||
| Femara | Tamoxifen | Femara | Tamoxifen | |||||
| Adverse Reactions | N = 2448 | N = 2447 | N = 2448 | N = 2447 | ||||
| n (%) | n (%) | n (%) | n (%) | |||||
| Patients with any adverse reaction | 2309 | (94.3) | 2212 | (90.4) | 636 | (26.0) | 606 | (24.8) |
| Hypercholesterolemia* | 1280 | (52.3) | 700 | (28.6) | 11 | (0.4) | 6 | (0.2) |
| Hot flashes* | 819 | (33.5) | 929 | (38.0) | - | - | - | - |
| Arthralgia/arthritis* | 621 | (25.4) | 504 | (20.6) | 84 | (3.4) | 50 | (2.0) |
| Bone fractures1 | 361 | (14.7) | 280 | (11.4) | - | - | - | - |
| Night sweats* | 356 | (14.5) | 426 | (17.4) | - | - | - | - |
| Weight increase* | 317 | (12.9) | 378 | (15.4) | 27 | (1.1) | 39 | (1.6) |
| Nausea* | 284 | (11.6) | 277 | (11.3) | 6 | (0.2) | 9 | (0.4) |
| Bone fractures**2 | 249 | (10.2) | 175 | (7.2) | - | - | - | - |
| Fatigue (lethargy, malaise, asthenia)* | 235 | (9.6) | 250 | (10.2) | 6 | (0.2) | 7 | (0.3) |
| Myalgia* | 221 | (9.0) | 212 | (8.7) | 18 | (0.7) | 14 | (0.6) |
| Vaginal bleeding* | 129 | (5.3) | 320 | (13.1) | 1 | (< 0.1) | 8 | (0.3) |
| Edema* | 164 | (6.7) | 160 | (6.5) | 3 | (0.1) | 1 | (< 0.1) |
| Weight decrease | 140 | (5.7) | 129 | (5.3) | 8 | (0.3) | 5 | (0.2) |
| Osteoporosis** | 126 | (5.1) | 67 | (2.7) | 10 | (0.4) | 5 | (0.2) |
| Back pain | 125 | (5.1) | 136 | (5.6) | 7 | (0.3) | 11 | (0.4) |
| Bone pain | 123 | (5.0) | 109 | (4.5) | 6 | (0.2) | 4 | (0.2) |
| Depression | 119 | (4.9) | 114 | (4.7) | 16 | (0.7) | 14 | (0.6) |
| Vaginal irritation* | 112 | (4.6) | 77 | (3.1) | 2 | (< 0.1) | 2 | (< 0.1) |
| Headache* | 105 | (4.3) | 94 | (3.8) | 8 | (0.3) | 4 | (0.2) |
| Pain in extremity | 103 | (4.2) | 79 | (3.2) | 6 | (0.2) | 4 | (0.2) |
| Osteopenia* | 87 | (3.6) | 76 | (3.1) | 0 | - | 3 | (0.1) |
| Dizziness/light-headedness* | 84 | (3.4) | 80 | (3.3) | 1 | (< 0.1) | 6 | (0.2) |
| Alopecia | 83 | (3.4) | 84 | (3.4) | - | - | - | - |
| Vomiting* | 80 | (3.3) | 80 | (3.3) | 3 | (0.1) | 5 | (0.2) |
| Cataract* | 49 | (2.0) | 54 | (2.2) | 16 | (0.7) | 17 | (0.7) |
| Constipation* | 49 | (2.0) | 71 | (2.9) | 3 | (0.1) | 1 | (< 0.1) |
| Myocardial infarction1 | 42 | (1.7) | 28 | (1.1) | - | - | - | - |
| Breast pain* | 37 | (1.5) | 43 | (1.8) | 1 | (< 0.1) | - | - |
| Anorexia* | 20 | (0.8) | 20 | (0.8) | 1 | (< 0.1) | 1 | (< 0.1) |
| Endometrial proliferation disorders* | 14 | (0.6) | 86 | (3.5) | 0 | - | 14 | (0.6) |
| Ovarian cyst* | 11 | (0.4) | 18 | (0.7) | 4 | (0.2) | 4 | (0.2) |
| Endometrial hyperplasia/cancer**1 | 11 | (0.4) | 72 | (2.9) | - | - | - | - |
| Endometrial hyperplasia/cancer**,3 | 6/1909 | (0.3) | 57/1943 | (2.9) | - | - | - | - |
| Other endometrial disorders* | 2 | (< 0.1) | 3 | (0.1) | 0 | - | 0 | - |
| Myocardial infarction**2 | 24 | (1.0) | 12 | (0.5) | - | - | - | - |
| Myocardial ischemia | 6 | (0.2) | 9 | (0.4) | - | - | - | - |
| Cerebrovascular accident/TIA**1 | 74 | (3.0) | 68 | (2.8) | - | - | - | - |
| Cerebrovascular accident/TIA**2 | 51 | (2.1) | 47 | (1.9) | - | - | - | - |
| Angina requiring surgery**1 | 35 | (1.4) | 33 | (1.3) | - | - | - | - |
| Angina requiring surgery**2 | 25 | (1.0) | 25 | (1.0) | - | - | - | - |
| Thromboembolic event**1 | 79 | (3.2) | 113 | (4.6) | - | - | - | - |
| Thromboembolic event**2 | 51 | (2.1) | 89 | (3.6) | - | - | - | - |
| Cardiac failure1 | 39 | (1.6) | 34 | (1.4) | - | - | - | - |
| Cardiac failure2 | 27 | (1.1) | 15 | (0.6) | - | - | - | - |
| Hypertension1 | 160 | (6.5) | 175 | (7.2) | - | - | - | - |
| Hypertension2 | 138 | (5.6) | 139 | (5.7) | - | - | - | - |
| Other cardiovascular**1 | 172 | (7.0) | 174 | (7.1) | - | - | - | - |
| Other cardiovascular**2 | 120 | (4.9) | 119 | (4.9) | - | - | - | - |
| Second primary malignancy1 | 129 | (5.3) | 150 | (6.1) | - | - | - | - |
| Second primary malignancy2 | 54 | (2.2) | 79 | (3.2) | - | - | - | - |
| *Target events pre-specified for analysis **Events pre-printed on CRF | ||||||||
| 1At median follow-up of 96 months (i.e., any time after randomization) for Femara (range up to 144 months) and 95 months for tamoxifen (range up to 143 months). 2At median treatment duration of 60 months (i.e. during treatment + 30 days after discontinuation of treatment) for Femara and tamoxifen (range up to 68 months). 3Excluding women who had undergone hysterectomy before study entry. TIA = Transient ischemic attack. Note: Cardiovascular events (including cerebrovascular and thromboembolic events), skeletal and urogenital/endometrial events and second primary malignancies were collected life -long. All of these events were assumed to be of CTC Grade 3 to 5 and were not individually graded. | ||||||||
| Adverse Reactions | Letrozole N = 2049 n (%) | Anastrozole N = 2062 n (%) | ||
| Grade 3/4 n (%) | All Grades n (%) | Grade 3/4 n (%) | All Grades n (%) | |
| Patients with at least one AR | 628 (30.6) | 2049 (100.0) | 591 (28.7) | 2062 (100.0) |
| Arthralgia | 80 (3.9) | 987 (48.2) | 69 (3.3) | 987 (47.9) |
| Hot flush | 17 (0.8) | 666 (32.5) | 9 (0.4) | 666 (32.3) |
| Fatigue | 8 (0.4) | 345 (16.8) | 10 (0.5) | 343 (16.6) |
| Osteoporosis | 5 (0.2) | 223 (10.9) | 11 (0.5) | 225 (10.9) |
| Myalgia | 16 (0.8) | 233 (11.4) | 15 (0.7) | 212 (10.3) |
| Back pain | 11 (0.5) | 212 (10.3) | 17 (0.8) | 193 (9.4) |
| Osteopenia | 4 (0.2) | 203 (9.9) | 1 (0.0) | 173 (8.4) |
| Pain in extremity | 9 (0.4) | 168 (8.2) | 3 (0.1) | 174 (8.4) |
| Lymphoedema | 5 (0.2) | 159 (7.8) | 2 (0.1) | 179 (8.7) |
| Insomnia | 7 (0.3) | 160 (7.8) | 3 (0.1) | 149 (7.2) |
| Hypercholesterolaemia | 2 (0.1) | 155 (7.6) | 1 (0.0) | 151 (7.3) |
| Hypertension | 25 (1.2) | 156 (7.6) | 20 (1.0) | 149 (7.2) |
| Depression | 16 (0.8) | 147 (7.2) | 13 (0.6) | 137 (6.6) |
| Bone pain | 10 (0.5) | 138 (6.7) | 9 (0.4) | 122 (5.9) |
| Nausea | 6 (0.3) | 137 (6.7) | 5 (0.2) | 152 (7.4) |
| Headache | 3 (0.1) | 130 (6.3) | 5 (0.2) | 168 (8.1) |
| Alopecia | 2 (0.1) | 127 (6.2) | 0 (0.0) | 134 (6.5) |
| Musculoskeletal pain | 6 (0.3) | 123 (6.0) | 9 (0.4) | 147 (7.1) |
| Radiation skin injury | 11 (0.5) | 120 (5.9) | 6 (0.3) | 88 (4.3) |
| Dyspnea | 16 (0.8) | 118 (5.8) | 10 (0.5) | 96 (4.7) |
| Cough | 1 (0.0) | 106 (5.2) | 1 (0.0) | 120 (5.8) |
| Musculoskeletal stiffness | 2 (0.1) | 102 (5.0) | 2 (0.1) | 84 (4.1) |
| Dizziness | 2 (0.2) | 94 (4.6) | 7 (0.3) | 109 (5.3) |
| Number (%) of Patients with Grade 1-4 Adverse Reactions | Number (%) of Patients with Grade 3-4 Adverse Reactions | |||
| Femara | Placebo | Femara | Placebo | |
| N = 2563 | N = 2573 | N = 2563 | N = 2573 | |
| Any Adverse Reactions | 2232 (87.1) | 2174 (84.5) | 419 (16.3) | 389 (15.1) |
| Vascular Disorders | 1375 (53.6) | 1230 (47.8) | 59 (2.3) | 74 (2.9) |
| Flushing | 1273 (49.7) | 1114 (43.3) | 3 (0.1) | 0 |
| General Disorders | 1154 (45) | 1090 (42.4) | 30 (1.2) | 28 (1.1) |
| Asthenia | 862 (33.6) | 826 (32.1) | 16 (0.6) | 7 (0.3) |
| Edema NOS | 471 (18.4) | 416 (16.2) | 4 (0.2) | 3 (0.1) |
| Musculoskeletal Disorders | 978 (38.2) | 836 (32.5) | 71 (2.8) | 50 (1.9) |
| Arthralgia | 565 (22) | 465 (18.1) | 25 (1) | 20 (0.8) |
| Arthritis NOS | 173 (6.7) | 124 (4.8) | 10 (0.4) | 5 (0.2) |
| Myalgia | 171 (6.7) | 122 (4.7) | 8 (0.3) | 6 (0.2) |
| Back Pain | 129 (5) | 112 (4.4) | 8 (0.3) | 7 (0.3) |
| Nervous System Disorders | 863 (33.7) | 819 (31.8) | 65 (2.5) | 58 (2.3) |
| Headache | 516 (20.1) | 508 (19.7) | 18 (0.7) | 17 (0.7) |
| Dizziness | 363 (14.2) | 342 (13.3) | 9 (0.4) | 6 (0.2) |
| Skin Disorders | 830 (32.4) | 787 (30.6) | 17 (0.7) | 16 (0.6) |
| Sweating Increased | 619 (24.2) | 577 (22.4) | 1 (< 0.1) | 0 |
| Gastrointestinal Disorders | 725 (28.3) | 731 (28.4) | 43 (1.7) | 42 (1.6) |
| Constipation | 290 (11.3) | 304 (11.8) | 6 (0.2) | 2 (< 0.1) |
| Nausea | 221 (8.6) | 212 (8.2) | 3 (0.1) | 10 (0.4) |
| Diarrhea NOS | 128 (5) | 143 (5.6) | 12 (0.5) | 8 (0.3) |
| Metabolic Disorders | 551 (21.5) | 537 (20.9) | 24 (0.9) | 32 (1.2) |
| Hypercholesterolemia | 401 (15.6) | 398 (15.5) | 2 (< 0.1) | 5 (0.2) |
| Reproductive Disorders | 303 (11.8) | 357 (13.9) | 9 (0.4) | 8 (0.3) |
| Vaginal Hemorrhage | 123 (4.8) | 171 (6.6) | 2 (< 0.1) | 5 (0.2) |
| Vulvovaginal Dryness | 137 (5.3) | 127 (4.9) | 0 | 0 |
| Psychiatric Disorders | 320 (12.5) | 276 (10.7) | 21 (0.8) | 16 (0.6) |
| Insomnia | 149 (5.8) | 120 (4.7) | 2 (< 0.1) | 2 (< 0.1) |
| Respiratory Disorders | 279 (10.9) | 260 (10.1) | 30 (1.2) | 28 (1.1) |
| Dyspnea | 140 (5.5) | 137 (5.3) | 21 (0.8) | 18 (0.7) |
| Investigations | 184 (7.2) | 147 (5.7) | 13 (0.5) | 13 (0.5) |
| Infections and Infestations | 166 (6.5) | 163 (6.3) | 40 (1.6) | 33 (1.3) |
| Renal Disorders | 130 (5.1) | 100 (3.9) | 12 (0.5) | 6 (0.2) |
| Adverse Reactions | Femara | Tamoxifen |
| 2.5 mg | 20 mg | |
| (N = 455) | (N = 455) | |
| % | % | |
| General Disorders | ||
| Fatigue | 13 | 13 |
| Chest Pain | 8 | 9 |
| Edema Peripheral | 5 | 6 |
| Pain NOS | 5 | 7 |
| Weakness | 6 | 4 |
| Investigations | ||
| Weight Decreased | 7 | 5 |
| Vascular Disorders | ||
| Hot Flushes | 19 | 16 |
| Hypertension | 8 | 4 |
| Gastrointestinal Disorders | ||
| Nausea | 17 | 17 |
| Constipation | 10 | 11 |
| Diarrhea | 8 | 4 |
| Vomiting | 7 | 8 |
| Infections/Infestations | ||
| Influenza | 6 | 4 |
| Urinary Tract Infection NOS | 6 | 3 |
| Injury, Poisoning and Procedural Complications | ||
| Post-Mastectomy Lymphedema | 7 | 7 |
| Metabolism and Nutrition Disorders | ||
| Anorexia | 4 | 6 |
| Musculoskeletal and Connective Tissue Disorders | ||
| Bone Pain | 22 | 21 |
| Back Pain | 18 | 19 |
| Arthralgia | 16 | 15 |
| Pain in Limb | 10 | 8 |
| Nervous System Disorders | ||
| Headache NOS | 8 | 7 |
| Psychiatric Disorders | ||
| Insomnia | 7 | 4 |
| Reproductive System and Breast Disorders | ||
| Breast Pain | 7 | 7 |
| Respiratory, Thoracic and Mediastinal Disorders | ||
| Dyspnea | 18 | 17 |
| Cough | 13 | 13 |
| Chest Wall Pain | 6 | 6 |
| 1Includes peripheral edema, leg edema, dependent edema, edema. 2Includes musculoskeletal pain, skeletal pain, back pain, arm pain, leg pain. 3Includes rash, erythematous rash, maculopapular rash, psoriasiform rash, vesicular rash. | ||||
| Adverse Reactions | Pooled | Pooled | Megestrol | |
| Femara | Femara | Acetate | Aminoglutethimide | |
| 2.5 mg | 0.5 mg | 160 mg | 500 mg | |
| (N = 359) | (N = 380) | (N = 189) | (N = 178) | |
| % | % | % | % | |
| Body as a Whole | ||||
| Chest Pain | 6 | 3 | 7 | 3 |
| Peripheral Edema1 | 5 | 5 | 8 | 3 |
| Asthenia | 4 | 5 | 4 | 5 |
| Weight Increase | 2 | 2 | 9 | 3 |
| Cardiovascular | ||||
| Hypertension | 5 | 7 | 5 | 6 |
| Digestive System | ||||
| Nausea | 13 | 15 | 9 | 14 |
| Vomiting | 7 | 7 | 5 | 9 |
| Constipation | 6 | 7 | 9 | 7 |
| Diarrhea | 6 | 5 | 3 | 4 |
| Pain-Abdominal | 6 | 5 | 9 | 8 |
| Anorexia | 5 | 3 | 5 | 5 |
| Dyspepsia | 3 | 4 | 6 | 5 |
| Infections/Infestations | ||||
| Viral Infection | 6 | 5 | 6 | 3 |
| Lab Abnormality | ||||
| Hypercholesterolemia | 3 | 3 | 0 | 6 |
| Musculoskeletal System | ||||
| Musculoskeletal2 | 21 | 22 | 30 | 14 |
| Arthralgia | 8 | 8 | 8 | 3 |
| Nervous System | ||||
| Headache | 9 | 12 | 9 | 7 |
| Somnolence | 3 | 2 | 2 | 9 |
| Dizziness | 3 | 5 | 7 | 3 |
| Respiratory System | ||||
| Dyspnea | 7 | 9 | 16 | 5 |
| Coughing | 6 | 5 | 7 | 5 |
| Skin and Appendages | ||||
| Hot Flushes | 6 | 5 | 4 | 3 |
| Rash3 | 5 | 4 | 3 | 12 |
| Pruritus | 1 | 2 | 5 | 3 |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Based on postmarketing reports, findings from animal studies and the mechanism of action, Femara can cause fetal harm and is contraindicated for use in pregnant women. In post-marketing reports, use of letrozole during pregnancy resulted in cases of spontaneous abortions and congenital birth defects; however, the data are insufficient to inform a drug-associated risk [see Contraindications (4), Warnings and Precautions (5.6), Adverse Reactions (6.2), and Clinical Pharmacology (12.1)].
In animal reproduction studies, administration of letrozole to pregnant animals during organogenesis resulted in increased post-implantation pregnancy loss and resorption, fewer live fetuses, and fetal malformation affecting the renal and skeletal systems in rats and rabbits at doses approximately 0.1 times the daily maximum recommended human dose (MRHD) on a mg/m 2 basis (see Data). The background risk of major birth defects and miscarriage for the indicated population is unknown.
However, the background risk in the U.S. general population of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies. Data Animal Data In a fertility and early embryonic development toxicity study in female rats, oral administration of letrozole starting 2 weeks before mating until pregnancy day 6 resulted in an increase in pre-implantation loss at doses ≥ 0.003 mg/kg/day (approximately 0.01 times the maximum recommended human dose on a mg/m 2 basis).
In an embryo-fetal developmental toxicity study in rats, daily administration of oral letrozole during the period of organogenesis at doses ≥ 0.003 mg/kg (approximately 0.01 time the maximum recommended human dose on a mg/m 2 basis) resulted in embryo-fetal toxicity including intrauterine mortality, increased resorptions and postimplantation loss, decreased numbers of live fetuses and fetal anomalies, including absence and shortening of renal papilla, dilation of ureter, edema, and incomplete ossification of frontal skull and metatarsals. Letrozole was teratogenic to rats at a dose of 0.03 mg/kg (approximately 0.01 times the maximum recommended human dose on a mg/m 2 basis) and caused fetal domed head and cervical/centrum vertebral fusion.
In the embryo-fetal development toxicity study in rabbits, daily administration of oral letrozole during the period of organogenesis at doses ≥ 0.002 mg/kg (approximately 0.01 times the maximum recommended human dose on a mg/m 2 basis) resulted in embryo-fetal toxicity, including intrauterine mortality, increased resorption, increased postimplantation loss and decreased numbers of live fetuses. Fetal anomalies included incomplete ossification of the skull, sternebrae, and fore- and hind legs.
Mechanism of action
12.1 Mechanism of Action The growth of some cancers of the breast is stimulated or maintained by estrogens. Treatment of breast cancer thought to be hormonally responsive (i.e., estrogen and/or progesterone receptor positive or receptor unknown) has included a variety of efforts to decrease estrogen levels (ovariectomy, adrenalectomy, hypophysectomy) or inhibit estrogen effects (antiestrogens and progestational agents).
These interventions lead to decreased tumor mass or delayed progression of tumor growth in some women. In postmenopausal women, estrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens (primarily androstenedione and testosterone) to estrone and estradiol. The suppression of estrogen biosynthesis in peripheral tissues and in the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme.
Letrozole is a nonsteroidal competitive inhibitor of the aromatase enzyme system; it inhibits the conversion of androgens to estrogens. In adult nontumor- and tumor-bearing female animals, letrozole is as effective as ovariectomy in reducing uterine weight, elevating serum LH, and causing the regression of estrogen-dependent tumors.
In contrast to ovariectomy, treatment with letrozole does not lead to an increase in serum FSH. Letrozole selectively inhibits gonadal steroidogenesis but has no significant effect on adrenal mineralocorticoid or glucocorticoid synthesis. Letrozole inhibits the aromatase enzyme by competitively binding to the heme of the cytochrome P450 subunit of the enzyme, resulting in a reduction of estrogen biosynthesis in all tissues.
Treatment of women with letrozole significantly lowers serum estrone, estradiol and estrone sulfate and has not been shown to significantly affect adrenal corticosteroid synthesis, aldosterone synthesis, or synthesis of thyroid hormones.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics In postmenopausal patients with advanced breast cancer, daily doses of 0.1 mg to 5 mg Femara (letrozole) suppress plasma concentrations of estradiol, estrone, and estrone sulfate by 75% to 95% from baseline with maximal suppression achieved within two-three days. Suppression is dose-related, with doses of 0.5 mg and higher giving many values of estrone and estrone sulfate that were below the limit of detection in the assays.
Estrogen suppression was maintained throughout treatment in all patients treated at 0.5 mg or higher. Letrozole is highly specific in inhibiting aromatase activity. There is no impairment of adrenal steroidogenesis. No clinically-relevant changes were found in the plasma concentrations of cortisol, aldosterone, 11-deoxycortisol, 17-hydroxy-progesterone, ACTH or in plasma renin activity among postmenopausal patients treated with a daily dose of Femara 0.1 mg to 5 mg.
The ACTH stimulation test performed after 6 and 12 weeks of treatment with daily doses of 0.1, 0.25, 0.5, 1, 2.5, and 5 mg did not indicate any attenuation of aldosterone or cortisol production. Glucocorticoid or mineralocorticoid supplementation is, therefore, not necessary. No changes were noted in plasma concentrations of androgens (androstenedione and testosterone) among healthy postmenopausal women after 0.1, 0.5, and 2.5 mg single doses of Femara or in plasma concentrations of androstenedione among postmenopausal patients treated with daily doses of 0.1 mg to 5 mg.
This indicates that the blockade of estrogen biosynthesis does not lead to accumulation of androgenic precursors. Plasma levels of LH and FSH were not affected by letrozole in patients, nor was thyroid function as evaluated by TSH levels, T3 uptake, and T4 levels.
Pharmacokinetics
It is metabolized slowly to an inactive metabolite whose glucuronide conjugate is excreted renally, representing the major clearance pathway.
Letrozole’s terminal elimination half-life is about 2 days and steady-state plasma concentration after daily 2.5 mg dosing is reached in 2-6 weeks.
Elimination Metabolism and Excretion: Metabolism to a pharmacologically-inactive carbinol metabolite (4,4'-methanol-bisbenzonitrile) and renal excretion of the glucuronide conjugate of this metabolite is the major pathway of letrozole clearance.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Absorption and Distribution: Letrozole is rapidly and completely absorbed from the gastrointestinal tract and absorption is not affected by food. It is metabolized slowly to an inactive metabolite whose glucuronide conjugate is excreted renally, representing the major clearance pathway. About 90% of radiolabeled letrozole is recovered in urine.
Letrozole’s terminal elimination half-life is about 2 days and steady-state plasma concentration after daily 2.5 mg dosing is reached in 2-6 weeks. Plasma concentrations at steady state are 1.5 to 2 times higher than predicted from the concentrations measured after a single dose, indicating a slight non-linearity in the pharmacokinetics of letrozole upon daily administration of 2.5 mg.
These steady-state levels are maintained over extended periods, however, and continuous accumulation of letrozole does not occur. Letrozole is weakly protein bound and has a large volume of distribution (approximately 1.9 L/kg). Elimination Metabolism and Excretion: Metabolism to a pharmacologically-inactive carbinol metabolite (4,4'-methanol-bisbenzonitrile) and renal excretion of the glucuronide conjugate of this metabolite is the major pathway of letrozole clearance.
Of the radiolabel recovered in urine, at least 75% was the glucuronide of the carbinol metabolite, about 9% was two unidentified metabolites, and 6% was unchanged letrozole. In human microsomes with specific CYP isozyme activity, CYP3A4 metabolized letrozole to the carbinol metabolite while CYP2A6 formed both this metabolite and its ketone analog.
In human liver microsomes, letrozole inhibited CYP2A6 and CYP2C19, however, the clinical significance of these findings is unknown. Specific Populations Pediatric, Geriatric and Race: In the study populations (adults ranging in age from 35 to greater than 80 years), no change in pharmacokinetic parameters was observed with increasing age.
Differences in letrozole pharmacokinetics between adult and pediatric populations have not been studied. Differences in letrozole pharmacokinetics due to race have not been studied. Renal Impairment: In a study of volunteers with varying renal function (24-hour creatinine clearance: 9 to 116 mL/min), no effect of renal function on the pharmacokinetics of single doses of 2.5 mg of Femara was found.
In addition, in a study (AR/BC2) of 347 patients with advanced breast cancer, about half of whom received 2.5 mg Femara and half 0.5 mg Femara, renal impairment (calculated creatinine clearance: 20 to 50 mL/min) did not affect steady-state plasma letrozole concentrations. Hepatic Impairment: In a study of subjects with mild to moderate non-metastatic hepatic dysfunction (e.g., cirrhosis, Child-Pugh classification A and B), the mean area under curve (AUC) values of the volunteers with moderate hepatic impairment were 37% higher than in normal subjects, but still within the range seen in subjects without impaired function.
In a pharmacokinetic study, subjects with liver cirrhosis and severe hepatic impairment (Child-Pugh classification C, which included bilirubins about 2-11 times ULN with minimal to severe ascites) had two-fold increase in exposure (AUC) and 47% reduction in systemic clearance. Breast cancer patients with severe hepatic impairment are thus expected to be exposed to higher levels of letrozole than patients with normal liver function receiving similar doses of this drug [see Dosage and Administration (2. 5)].
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Letrozole 2.5 mg Film coated tablet | ₱30.00–₱35.00Reference ₱32.98 | per tablet | DPRI procurement range |
| Letrozole 2.5 mg Tablet | ₱31.50–₱35.00Reference ₱31.50 | per tablet | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Letrozole |
| PNF listing | Oral: 2.5 mg tablet/film-coated tablet |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Femara · Novartis Pharmaceuticals Corporation [US FDA-approved label, version 32, June 11, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=82b77d74-085f-45ac-a7dd-1f5c038bf406
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .